Tumours of the vagus nerve are rare — they account for fewer than 5% of all head and neck neoplasms — but their location along one of the body’s most important cranial nerves gives them clinical significance well beyond their frequency. The two most common types, schwannomas and paragangliomas, behave very differently and require distinct diagnostic and treatment approaches.
Vagal Schwannomas
Schwannomas are the most common tumour arising from the vagus nerve. They develop from Schwann cells, the support cells that produce the myelin sheath insulating nerve fibres. These are benign, slow-growing tumours that typically present as a painless, smooth, lateral neck mass in the parapharyngeal or carotid space.
Vagal schwannomas grow eccentrically — they push nerve fibres aside rather than infiltrating them, which is why neurological deficits are often absent at presentation despite the tumour sometimes reaching considerable size (3-6 cm or larger before detection is common). On MRI, they appear as well-circumscribed, ovoid masses with characteristic heterogeneous enhancement. Cystic degeneration and areas of haemorrhage are common in larger tumours, producing the “target sign” on T2-weighted imaging that helps distinguish them from other parapharyngeal masses.
Unlike vestibular schwannomas (acoustic neuromas), vagal schwannomas are not associated with hearing loss. However, they share a genetic link: neurofibromatosis type 2 (NF2), caused by mutations in the merlin/schwannomin gene on chromosome 22, predisposes individuals to multiple schwannomas throughout the nervous system, including the vagus nerve. Sporadic vagal schwannomas (not associated with NF2) are more common and typically present as solitary tumours.
Vagal Paragangliomas
Paragangliomas (also called glomus vagale tumours) arise from paraganglia — clusters of neuroendocrine cells — distributed along the vagus nerve, particularly at the nodose ganglion just below the skull base. Unlike schwannomas, they are vascular tumours with a rich blood supply, which has important implications for both imaging and surgery.
On CT angiography, vagal paragangliomas show intense enhancement and may display the “Lyre sign” — splaying of the internal and external carotid arteries by the tumour, analogous to the shape of a classical lyre. This angiographic appearance is nearly pathognomonic and helps distinguish paragangliomas from schwannomas before surgery.
Approximately 30-40% of head and neck paragangliomas are hereditary, linked to germline mutations in succinate dehydrogenase (SDH) subunit genes — particularly SDHB, SDHC, and SDHD. SDHB mutations carry a higher risk of malignancy (estimated 15-30% of cases) and should prompt whole-body surveillance for additional paragangliomas. Genetic testing is now recommended for all patients diagnosed with head and neck paragangliomas, regardless of family history. A small proportion of paragangliomas are functional, secreting catecholamines (noradrenaline, adrenaline, dopamine), which can cause episodic hypertension, palpitations, and flushing — biochemical screening with plasma or urine metanephrines is essential before any surgical intervention.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Clinical Presentation
Most vagal tumours present as a painless, slowly enlarging lateral neck mass. Because they originate deep in the carotid space, they may reach 4-6 cm before the patient or their doctor notices them. The mass typically displaces medially (pushing the oropharyngeal wall inward, visible on examination) and can be moved laterally but not vertically — a useful clinical sign.
Neurological symptoms depend on the tumour’s size and rate of growth. Common presenting symptoms include hoarseness (from vocal cord paresis due to compression of the recurrent or superior laryngeal nerve), dysphagia (from pharyngeal displacement), and ipsilateral tongue weakness (if the hypoglossal nerve is involved). Horner syndrome (ptosis, miosis, anhidrosis) can occur if the cervical sympathetic chain is compressed. Large tumours extending toward the jugular foramen may affect cranial nerves IX (glossopharyngeal), XI (accessory), and XII (hypoglossal).
Pain is uncommon with schwannomas but may occur with paragangliomas, particularly those with rapid growth or extracapsular extension. A pulsatile quality or audible bruit over the mass suggests a paraganglioma.
Diagnosis
MRI with gadolinium contrast is the primary imaging modality. It provides excellent soft-tissue detail, defines the tumour’s relationship to the carotid vessels and adjacent cranial nerves, and helps distinguish schwannomas from paragangliomas based on signal characteristics and enhancement patterns. CT angiography adds information about the vascular anatomy — essential for paragangliomas, where preoperative embolisation may be considered to reduce intraoperative bleeding.
For suspected paragangliomas, functional imaging with 68Ga-DOTATATE PET/CT has largely replaced older MIBG scans. DOTATATE PET is highly sensitive for somatostatin receptor-expressing neuroendocrine tumours and can detect multicentric disease — important given the 10-20% rate of multiple paragangliomas in hereditary cases.
Fine-needle aspiration biopsy is generally avoided for suspected paragangliomas due to bleeding risk and limited diagnostic yield. For schwannomas, biopsy may be performed when the diagnosis is uncertain, though MRI characteristics are often sufficient.
Treatment
Treatment decisions balance the risks of intervention against the natural history of these generally slow-growing tumours.
Surgery remains the definitive treatment when intervention is warranted. For schwannomas, the goal is complete excision via a transcervical approach. Because schwannomas typically displace rather than infiltrate nerve fibres, nerve-sparing excision is sometimes possible, with intracapsular enucleation preserving vagal function in favourable cases. However, for larger tumours or those that have incorporated the nerve, sacrifice of the vagus nerve may be unavoidable. Expected consequences of unilateral vagal sacrifice include ipsilateral vocal cord paralysis (producing hoarseness), dysphagia, and gastroparesis, though compensatory mechanisms often improve symptoms over months.
For paragangliomas, surgery is more complex due to the tumour’s vascularity and intimate relationship with the carotid vessels. Preoperative embolisation 24-72 hours before surgery can reduce blood loss. Cranial nerve deficits after paraganglioma surgery are common — reported rates of new vagal palsy range from 30% to over 50% in surgical series.
Stereotactic radiosurgery and fractionated radiotherapy are alternatives for paragangliomas, particularly in elderly patients, those with bilateral tumours (where bilateral vagal sacrifice would be devastating), or those who decline surgery. Radiation does not typically shrink the tumour but controls growth, with local control rates exceeding 90% at 5-10 years in published series.
Observation is appropriate for small, asymptomatic tumours in elderly patients or those with significant comorbidities. Serial MRI monitoring (every 6-12 months initially, then annually) tracks growth rate and guides the timing of any future intervention.
Prognosis
Vagal schwannomas are overwhelmingly benign. Malignant transformation is extremely rare (under 1%), and recurrence after complete excision is uncommon. The main long-term issue is cranial nerve deficit from surgery.
Vagal paragangliomas are more variable. Most are benign, but SDHB-mutated tumours carry a meaningful risk of malignancy, with potential for distant metastasis to lymph nodes, lungs, liver, and bone. Lifelong surveillance is recommended for hereditary cases. For all patients, regular follow-up after treatment monitors for recurrence, contralateral disease, and the functional consequences of any cranial nerve deficits.
Want a clear, science-backed guide to the vagus nerve — from its anatomy to the conditions that affect it? Get My Vagus Nerve & Me eBook for the full picture.
